Longevity & AgingClinical TrialPaywall

Researchers Test Whether Blood Clot Survivors Carry Hidden Clonal Hematopoiesis Mutations

A completed French registry-style study asked whether people with past venous thromboembolism carry CHIP mutations, an age-linked blood stem cell change. No results are posted.

Saturday, November 21, 2026 1 view
Published in ClinicalTrials.gov
a hematology lab technician loading blood sample tubes into a DNA sequencing machine

Summary

Clonal hematopoiesis of indeterminate potential (CHIP) happens when blood stem cells pick up mutations and their descendants expand, something that becomes more common with age. CHIP has been linked to higher risks of blood cancers and cardiovascular disease. This study, sponsored by the Centre Hospitalier Universitaire de Nîmes in France, set out to find out whether people with a history of venous thromboembolism (VTE), meaning blood clots in the veins, carry CHIP mutations. The investigators assumed these patients would show such mutations. The registry entry lists the study as completed, but the abstract gives no results, no participant numbers, and no design details. So this is a record of a question being asked, not an answer. It matters because if CHIP turns out to be tied to clotting, it could point to an aging-related blood mechanism and a possible way to flag people at higher risk.

Detailed Summary

Why this matters: Clonal hematopoiesis of indeterminate potential (CHIP) is an age-related condition in which blood stem cells acquire mutations, often in genes such as DNMT3A, TET2 and ASXL1, and the mutated clones expand. CHIP is a recognized marker of biological aging and has been associated with blood cancers, atherosclerotic cardiovascular disease and inflammation. Whether it also contributes to venous clots is a question with clear relevance to healthspan.

What was studied: This ClinicalTrials.gov record (NCT04477564), sponsored by the Centre Hospitalier Universitaire de Nîmes, describes a study investigating whether CHIP exists in patients with a history of venous thromboembolism (VTE). The investigators state an assumption that these patients carry CHIP-related mutations. The registry lists the status as completed.

Key results: None are available. The abstract does not report how many patients were enrolled, how they were selected, whether a control group was used, which sequencing method or variant allele frequency threshold defined CHIP, or what was found. No outcome data are provided, so no claim can be made that CHIP is more common in VTE, or that it causes clots.

Implications: The mechanistic idea is plausible and worth watching. Mutated blood cells can drive inflammatory signaling and may influence clotting pathways, so CHIP could be a marker of clot risk, or a contributor to it. If a published report confirms a higher prevalence, CHIP testing might eventually help refine risk assessment in clot survivors. That would still require larger, controlled studies, and evidence that testing changes outcomes.

Caveats: This summary is based only on a registry description, not on peer-reviewed data. The investigators' hypothesis is a stated expectation, not a finding. Readers and clinicians should look for the eventual publication before drawing any conclusions, and should not change care based on this entry.

Key Findings

  • The study asks whether patients with prior venous thromboembolism carry CHIP mutations.
  • Investigators hypothesized that these patients would show CHIP-related mutations; this is an assumption, not a result.
  • The registry lists the study as completed, but no results, sample size, or design details appear in the abstract.
  • CHIP is an age-related blood stem cell change already linked to blood cancer and cardiovascular risk in other work.

Methodology

The available text describes an investigation of CHIP in patients with a history of venous thromboembolism, sponsored by the Centre Hospitalier Universitaire de Nîmes. Design, sample size, control group, sequencing method, and endpoints are not stated. Evidence level cannot be graded from this record.

Study Limitations

This summary is based on the registry abstract only and contains no results, numbers, or methods. The hypothesis is untested in the supplied text, and any link between CHIP and venous thromboembolism, whether association or causation, remains unestablished here. Publication and peer review are needed before conclusions.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: